Takeda Pharmaceutical (TAK) Operating Income (QoQ) (2018 - 2026)
Powered by 
Analysis
Takeda Pharmaceutical (TAK) Operating Income (QoQ) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 646.13 Bn | 625.38 Bn | 17.26 Bn |
| 2 | AbbVie | 442.39 Bn | 435.82 Bn | 12.70 Bn |
| 3 | Merck | 366.26 Bn | 359.12 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.58 Bn | 258.89 Bn | 11.24 Bn |
| 5 | Pfizer | 159.00 Bn | 147.30 Bn | 10.94 Bn |
| 6 | Sanofi | 52.39 Bn | 45.00 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - |
| 8 | Incyte | 25.41 Bn | 20.87 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.54 Bn | 18.88 Bn | 683.80 Mn |
| 10 | Takeda Pharmaceutical | 2.61 Bn | -3.19 Bn | 5.10 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.60% |
| Mar 31, 2026 | 147.49% |
| Dec 31, 2025 | -194.34% |
| Sep 30, 2025 | 124.74% |
| Jun 30, 2025 | 5.42% |
| Mar 31, 2025 | 345.59% |
| Dec 31, 2024 | -117.60% |
| Sep 30, 2024 | 161.96% |
| Jun 30, 2024 | -6.08% |
| Mar 31, 2024 | 89.80% |
| Dec 31, 2023 | -78.46% |
| Sep 30, 2023 | 126.25% |
| Jun 30, 2023 | -3.50% |
| Mar 31, 2023 | 22.51% |
| Dec 31, 2022 | 37.59% |
| Sep 30, 2022 | -35.03% |
| Jun 30, 2022 | -45.59% |
| Mar 31, 2022 | 108.75% |
| Dec 31, 2021 | 15.79% |
| Sep 30, 2021 | -61.02% |